Clinical trial
Phase 2 Study of MM-093 to Treat Patients With Uveitis
NCT00444743 · Merrimack Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00444743 |
|---|---|
| Title | Phase 2 Study of MM-093 to Treat Patients With Uveitis |
| Official title | A Phase 2, Double - Blind, Placebo - Controlled, Randomized Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis |
| Lead sponsor | Merrimack Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Uveitis |
| Intervention type | Drug, Other |
| Interventions | MM-093, Placebo |
| Enrollment | 20 |
| Start date | Feb 1, 2007 |
| Primary completion | Nov 1, 2008 |
| First posted | Mar 8, 2007 |
| Last update posted | Dec 18, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: